BlackRock, Inc. 13D and 13G filings for Marinus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-07-08 4:32 pm Sale |
2024-06-30 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
BlackRock Inc. BLK |
1,869,949 3.400% |
-2,729,329 (-59.34%) |
Filing |
| 2024-01-25 4:59 pm Purchase |
2023-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
BlackRock Inc. BLK |
4,599,278 8.400% |
3,657,967 (+388.60%) |
Filing |
| 2022-07-08 4:56 pm Sale |
2022-06-30 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
BlackRock Inc. BLK |
941,311 2.500% |
-2,075,578 (-68.80%) |
Filing |
| 2022-02-02 7:18 pm Purchase |
2021-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
BlackRock Inc. BLK |
3,016,889 8.200% |
936,798 (+45.04%) |
Filing |
| 2021-02-02 2:56 pm Purchase |
2020-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
BlackRock Inc. BLK |
2,080,091 5.800% |
2,080,091 (New Position) |
Filing |